Literature DB >> 2214798

Long-term experience with a totally implanted catheter system in cancer patients.

C O Freytes1, P Reid, K L Smith.   

Abstract

Long-term experience with totally implanted catheter systems (TICS) is limited. We retrospectively evaluated the performance and long-term complications of TICS for intravenous infusion in cancer patients; 134 systems were implanted in 128 patients. The median duration of implantation was 144 weeks with 49 systems implanted for more than one year. Complications related to surgical factors included malposition of reservoir (2%), skin perforation or wound dehiscence (1.5%) and pneumothorax (less than 1%). Complications not related to surgical factors included: drug extravasation (1.5%), mechanical malfunction (1.5%), vein thrombosis (less than 1%), clotting of the reservoir or catheter (2%), skin infection (1.5%), and sepsis (less than 1%). The total complication rate was 13%. Most complications resolved spontaneously or with medical treatment and only 6 patients (4.6%) required re-implantation of a second system. We conclude that with long-term usage of TICS, the complication rate remains low, making it a safe and viable alternative for patients requiring long-term intravenous therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214798     DOI: 10.1002/jso.2930450208

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Catheter migration of a Port-a-cath system.

Authors:  G Bruninx; J C Matte; F VanWilder; C Delcour
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Nov-Dec       Impact factor: 2.740

Review 2.  Totally implantable catheter migration and its percutaneous retrieval: case report and review of the literature.

Authors:  E Intagliata; F Basile; R Vecchio
Journal:  G Chir       Date:  2017 Sep-Oct

3.  Totally implantable venous access ports and associated complications in sub-Saharan Africa: a single-centre retrospective analysis.

Authors:  Kahmil Salawu; Oreoluwa Arowojolu; Oluwasegun Afolaranmi; Mutiu Jimoh; Chukwumere Nworgu; Bode Falase
Journal:  Ecancermedicalscience       Date:  2022-05-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.